donanemab + dexamethasone

**Donanemab + dexamethasone** is a combination of two pharmaceuticals: - **Donanemab** is a humanized monoclonal antibody targeting deposited amyloid beta plaques in the brain, specifically insoluble N-truncated pyroglutamate amyloid beta commonly found in mature plaques. It binds these plaques and facilitates their removal via immune activation, primarily slowing cognitive and functional decline in early Alzheimer's disease[2][1][4]. - **Dexamethasone** is a synthetic glucocorticoid corticosteroid. It modulates inflammation and immune response by binding glucocorticoid receptors, suppressing pro-inflammatory cytokine production, and inhibiting multiple inflammatory pathways. While donanemab is indicated for Alzheimer's disease and frequently administered intravenously, dexamethasone is commonly used as a premedication to mitigate infusion-related reactions, including possible inflammatory or allergic responses, and is used in a wide variety of other diseases. There is no evidence that this combination is itself a commercial drug product or that it is used as a structured fixed-dose combination; instead, dexamethasone may be given as an adjunct or premedication in donanemab therapy[2].

Other names

donanemab-azbtdexamethasone